文献速递复苏、休克与脓毒症心脑血管急症

乳酸给药对心脏骤停后心肌功能障碍的影响:一项离体研究

Effects of Lactate Administration on Postcardiac Arrest Myocardial Dysfunction: An Ex Vivo Study.
PubMed 文献 · Shock · 2025-12-02
一句话结论离体大鼠心脏模型显示,乳酸给药未改善心脏骤停后心肌功能,也未造成损害,提示体内获益可能非直接心肌效应。

本研究采用离体大鼠心脏模型,经历20分钟不可除颤心脏骤停后40分钟再灌注,分为对照组、乳酸组(20 mmol/L L-乳酸)、延迟乳酸组(再灌注5分钟后给乳酸)和高渗乳酸组。结果显示,再灌注末速率压力乘积恢复在对照组为基线的47%±4%,乳酸组45%±4%、延迟组40%±3%、高渗组42%±3%,组间无显著差异;左室舒张末压、冠脉流量、心律失常发生率、肌钙蛋白和肌酸激酶释放、线粒体功能在各组间均无显著差异。结论认为乳酸给药未改善也未损害心脏骤停后心肌功能,体内获益可能非直接心肌效应。

要点

  • 离体大鼠心脏心脏骤停后,20 mmol/L L-乳酸再灌注未改善速率压力乘积恢复(对照组47%±4% vs 乳酸组45%±4%,P=ns)。
  • 乳酸给药未增加心律失常(对照组44% vs 乳酸组33%,P=ns),未加重心肌损伤(肌钙蛋白和肌酸激酶无显著差异)。
  • 延迟5分钟给乳酸或高渗乳酸均未显示获益(速率压力乘积恢复40%±3%和42%±3%,P=ns)。
  • 线粒体功能在心脏骤停后显著受损,但乳酸组与对照组无显著差异。

适用人群与场景

  • 离体大鼠心脏,经历20分钟不可除颤心脏骤停后40分钟再灌注。

研究设计与关键结果

  • 研究类型:离体大鼠心脏实验;样本量:对照组n=9,乳酸组n=9,延迟乳酸组n=5,高渗乳酸组n=6。
  • 干预:再灌注时给予含20 mmol/L L-乳酸的Krebs缓冲液;对照用标准Krebs缓冲液;延迟组再灌注5分钟后给乳酸;高渗组用含Na+ 163 mmol/L的高渗Krebs加20 mmol/L L-乳酸。
  • 主要终点:再灌注末速率压力乘积恢复为基线的百分比,对照组47%±4%,乳酸组45%±4%,延迟组40%±3%,高渗组42%±3%,组间无显著差异(P=ns)。
  • 次要终点:左室舒张末压和冠脉流量组间可比;室性心律失常发生率对照组44%、乳酸组33%、延迟组40%、高渗组50%(P=ns);肌钙蛋白和肌酸激酶释放对照组与乳酸组相似(P=ns);线粒体功能在心脏骤停后显著受损,但两组间无显著差异。

证据类型、等级与局限

  • 证据类型:离体动物实验;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,离体条件下乳酸给药未改善心脏骤停后心肌功能且无损害,提示体内获益不太可能由直接心肌效应所致。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In vivo studies have reported cardiovascular benefits of lactate administration after cardiac arrest (CA). However, it remains unclear whether these improvements are due to direct or indirect myocardial effects of lactate. Therefore, we investigated the effects of lactate administration in an ex vivo CA model.

METHODS: Isolated rat hearts were subjected to 20 minutes of nonshockable CA followed by 40 minutes of reperfusion. Four groups were analyzed: Control (n = 9), reperfused with standard Krebs buffer; lactate (n = 9), reperfused with Krebs containing 20 mmol/L L-lactate; Lact 5min (n = 5), reperfused with Krebs for 5 minutes and then with Krebs containing 20 mmol/L L-lactate; Lact Hyper (n = 6), reperfused with hypertonic (Na + 163 mmol/L) Krebs containing 20 mmol/L L-lactate. Endpoints included rate-pressure product, left ventricular end-diastolic pressure, coronary flow, and arrhythmia incidence. Troponin and creatine kinase release, mitochondrial calcium retention capacity, and mitochondrial respiration were assessed.

RESULTS: Rate-pressure product recovery at the end of reperfusion was 47% ± 4% of baseline in Control versus 45% ± 4%, 40% ± 3%, and 42% ± 3% in Lactate, Lact 5min , and Lact Hyper ( P = ns). Left ventricular end-diastolic pressure and coronary flow were comparable across the groups. Ventricular arrhythmias occurred in 44%, 33%, 40%, and 50% of hearts, respectively ( P = ns). Troponin and creatine kinase levels were similar ( P = ns) between Controls and Lactate-treated hearts. Mitochondrial functions, which were significantly impaired by CA, did not differ significantly between the two groups.

CONCLUSIONS: Lactate administration did not improve post-CA myocardial function and was not deleterious. These findings suggest that the in vivo benefits of lactate administration are unlikely due to direct myocardial effects.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Stevic N, Ferrera R, Baetz D, et al. Effects of Lactate Administration on Postcardiac Arrest Myocardial Dysfunction: An Ex Vivo Study. Shock. 2025. PMID: 41427922. doi:10.1097/SHK.0000000000002770

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。